Application of Fuxia dothidei YG0564 in preparation of composition for preventing or treating sexual precocious puberty, impaired growth and development and / or obesity

Abstract

The invention provides an application of Fuxia dothidei YG0564 in preparation of a composition for preventing, relieving and / or treating individual sexual precocity, growth and development impairment and / or obesity. It is found that the Fuxia dolferi YG0564 can effectively prevent, relieve and / or treat sexual precocious puberty, growth and development damage and / or obesity of individuals, and especially has a remarkable improvement effect on the diseases caused by high-fat diet. For sexual precocious puberty or damaged growth and development induced by high-fat diet, the Fuxia dolferi YG0564 is applied to individuals in the early stage or early stage of puberty, the protection effect of the Fuxia dolferi YG0564 can be continued to the adult stage, and the fundamental problem of growth and development is solved through staged medication. Therefore, a potential probiotic treatment scheme is provided for precocious puberty, growth and development damage and / or obesity of individuals, and the probiotic composition is convenient to apply, high in patient acceptability and low in treatment cost, so that the probiotic composition has good clinical transformation value and social benefits.

Description

Technical Field

[0001] This invention relates to the field of microbiology, and more specifically to the use of *Foscias dorsalis* YG0564 in the preparation of compositions for the prevention, relief and / or treatment of individual precocious puberty, impaired growth and / or obesity, and in compositions for promoting height development in minors. Background Technology

[0002] Globally, obesity caused by overnutrition has become a prominent public health challenge and is closely linked to impaired growth and development. Among these, high-fat diets (HFD) have a particularly significant adverse effect on children's growth and development.

[0003] Specifically, a high-fat diet can interfere with growth and development through multiple pathways: First, it can cause skeletal growth disorders, leading to dysfunction of the elongation plate and affecting bone maturity. This disorder may cause premature fusion of long bone epiphyses, shortening the window of height growth and negatively impacting an individual's final height. Second, a high-fat diet is a significant contributing factor to central precocious puberty (CPP). It accelerates the onset of puberty through multiple mechanisms, including activating the hypothalamic-pituitary-gonadal axis (HPG axis), disrupting the secretion of hormones such as leptin and sex hormones, and triggering inflammatory responses. Clinical and animal studies have shown that exposure to a high-fat diet significantly increases the incidence of precocious puberty, and is more pronounced in females, which may be related to sex-specific physiological differences.

[0004] It is worth noting that precocious puberty has a significant negative impact on height development. Children with precocious puberty often experience premature epiphyseal closure and advanced bone age, which directly compresses growth potential and limits final height. In a high-fat diet-induced model, the negative impact of precocious puberty on height is particularly prominent, indicating that it is an important pathway mediating height impairment.

[0005] Currently, existing treatments for the above problems have significant limitations: in the treatment of central precocious puberty, gonadotropin-releasing hormone analogues (GnRHa) are the core approach, but this method requires long-term injections, has local side effects, and carries a heavy economic burden. It also needs to be combined with psychological support and lifestyle interventions, and dynamic assessments must be conducted in strict accordance with medical advice. Hormone treatments for growth retardation also face problems such as low compliance and heavy economic burden.

[0006] Therefore, developing non-invasive, safe, and economical treatments to address issues such as precocious puberty, impaired growth and development, and obesity caused by high-fat diets is an urgent clinical need and of significant practical importance. Summary of the Invention

[0007] Purpose of the invention

[0008] The purpose of this invention is to provide the use of Phocaeicola dorei YG0564 in the preparation of compositions for the prevention, relief and / or treatment of individual precocious puberty, impaired growth and development and / or obesity. Phocaeicola dorei YG0564 is deposited at the China General Microbiological Culture Collection Center (CGMCC), classified as Phocaeicola dorei, with a deposit date of June 7, 2023, and accession number CGMCC No. 27578.

[0009] Solution

[0010] To achieve the objectives of this invention, the following technical solution is adopted.

[0011] In the following technical solution, Phocaeicola dorei YG0564 is deposited at the China General Microbiological Culture Collection Center (CGMCC), and its classification name is Phocaeicola dorei. The deposit date is June 7, 2023, and the deposit number is CGMCC No. 27578.

[0012] In a first aspect, the present invention provides the use of Phocaeicola dorei YG0564 in the preparation of compositions for the prevention, relief and / or treatment of individual precocious puberty.

[0013] In a feasible implementation, the individual is a mammal, preferably a female mammal, and more preferably a human.

[0014] In a feasible implementation, the individual precocious puberty is precocious puberty induced by a high-fat diet.

[0015] In feasible implementations, the prevention, mitigation, and / or treatment of individual precocious puberty includes reversing the early onset of puberty and delaying the onset of puberty. Experimental studies have shown that Phocaeicola dorei YG0564 may delay puberty by reducing sex hormone levels upregulated by a high-fat diet, thereby delaying follicular development and ultimately delaying puberty.

[0016] In a feasible implementation, *Focusia dorsalis* YG0564 is the sole active ingredient or one of the active ingredients in the composition.

[0017] In feasible embodiments, the composition is a pharmaceutical composition, or a food composition and / or health product composition for non-therapeutic purposes.

[0018] In a second aspect, the present invention provides the use of Phocaeicola dorei YG0564 in the preparation of compositions for the prevention, mitigation and / or treatment of impaired individual growth and development.

[0019] In a feasible implementation, the individual is a mammal, preferably a female mammal, and more preferably a human.

[0020] In a feasible implementation, the impaired growth and development refers to growth and development impairment caused by a high-fat diet, such as growth inhibition caused by a high-fat diet. Experimental verification shows that Phocaeicola dorei YG0564 can effectively alleviate growth and development impairment caused by a high-fat diet and promote normal growth and development in individuals.

[0021] In a feasible implementation, *Focusia dorsalis* YG0564 is the sole active ingredient or one of the active ingredients in the composition.

[0022] In feasible embodiments, the composition is a pharmaceutical composition, or a food composition and / or health product composition for non-therapeutic purposes.

[0023] Thirdly, the present invention provides the use of Phocaeicola dorei YG0564 in the preparation of compositions for the prevention and / or treatment of individual obesity or obesity-related diseases.

[0024] In a feasible implementation, the individual is a mammal, preferably a male mammal, and more preferably a human.

[0025] In a feasible implementation, the obesity is obesity caused by a high-fat diet.

[0026] In a feasible implementation, the obesity-related diseases are the following diseases caused by obesity: hyperlipidemia, hypertension, diabetes, coronary heart disease, non-alcoholic fatty liver disease, chronic obstructive pulmonary disease, polycystic ovary syndrome and / or hypothyroidism.

[0027] In a feasible implementation, *Focusia dorsalis* YG0564 is the sole active ingredient or one of the active ingredients in the composition.

[0028] In feasible embodiments, the composition is a pharmaceutical composition, or a food composition and / or health product composition for non-therapeutic purposes.

[0029] Of all the above uses, it is feasible to use Phocaeicola dorei YG0564 as an inactivated strain.

[0030] Fourthly, the present invention provides a method for preventing, alleviating and / or treating individual precocious puberty, impaired growth and development and / or obesity, comprising: administering to a subject in need an effective amount of *Focusella dorsalis* YG0564 or a composition containing therein.

[0031] In a feasible implementation, the individual is a mammal, preferably a human.

[0032] Suitablely, in cases where the indication is precocious puberty or impaired growth and development, the individual is female; in cases where the indication is obesity, the individual is male.

[0033] In a feasible implementation, the precocious puberty, impaired growth and development, and / or obesity are caused by a high-fat diet.

[0034] In a feasible implementation, the Phocaeicola dorei YG0564 is the strain in the following forms: live bacteria, inactivated cells, lysate, and / or fermentation supernatant.

[0035] In a feasible implementation, *Focusia dorsalis* YG0564 is the sole active ingredient or one of the active ingredients in the composition.

[0036] Beneficial effects

[0037] This invention is the first to discover and confirm that *Focius dorsalis* YG0564 can effectively prevent, alleviate and / or treat precocious puberty, impaired growth and development and / or obesity in individuals, especially showing significant improvement in these conditions caused by a high-fat diet, thus expanding the application prospects of this strain in the treatment of growth and development-related diseases.

[0038] Furthermore, the inventors discovered that for precocious puberty or impaired growth and development induced by a high-fat diet, the protective effect of *Focusia dorsalis* YG0564 administered to individuals in the pre-pubertal or early pubertal period can extend into adulthood. This characteristic enables the fundamental solution to growth and development problems through phased medication, not only providing long-term protection for children's growth and development but also effectively reducing the potential risks and economic burdens associated with long-term medication.

[0039] In addition, this invention addresses the different symptoms caused by high-fat diets in females and males by implementing precise intervention strategies: for female individuals, *Focusia dorsalis* YG0564 focuses more on improving precocious puberty and impaired growth and development; for male individuals, it primarily aims to alleviate obesity symptoms, demonstrating the advantages of sex-matched targeted therapy and enhancing the pertinence and effectiveness of the intervention.

[0040] In addition, the technical solution of the present invention has the following advantages: the application of *Focusella dorsalis* YG0564 does not require injection, which fundamentally avoids the local side effects and pain experienced by patients that may be caused by traditional treatment methods, and significantly improves the convenience of treatment and patient acceptance; at the same time, as a potential probiotic treatment solution, it is expected to reduce the overall treatment cost, alleviate the economic burden on families and society, and has good clinical translational value and social benefits. Attached Figure Description

[0041] One or more embodiments are illustrated by way of example with reference to the accompanying drawings, and these illustrative examples are not intended to limit the embodiments. The term "illustrative" as used herein means "serving as an example, embodiment, or illustration." Any embodiment illustrated herein as "illustrative" is not necessarily to be construed as superior to or better than other embodiments.

[0042] Figure 1 The results show that *Foscias dorsalis* YG0564 can prevent precocious puberty in female mice fed a high-fat diet. Figure A shows the time of first vaginal opening and prepuce separation in female mice and male mice in the ND and HFD groups, while Figure B shows the time of first vaginal opening and prepuce separation in female mice and male mice in the HFD and HFD+YG0564 groups. The dashed line represents the median, and the solid line represents the mean.

[0043] Figure 2 The results showed that *Focusia dorsalis* YG0564 could reduce the expression of sexual maturity genes in female mice fed a high-fat diet and delay ovarian sexual maturation. Figure A shows the expression levels of sexual maturity genes in the hypothalamus of female mice in each group; Figure B shows the expression levels of sexual maturity genes in the ovaries of female mice in each group; Figure C shows HE-stained sections of ovaries from female mice in each group, and a bar chart of ovarian counts (bottom left). *P<0.05, **P<0.01 compared to HFD; error bars represent standard deviation (SD).

[0044] Figure 3 The results showed that *Foscias dorsalis* YG0564 significantly promoted physical growth in female mice fed a high-fat diet. Figure A shows the net increase in body length for each group of female mice; Figure B shows the net increase in body weight for each group of female mice; Figure C shows the ovarian growth rate curve (cm / day) for each group of female mice; Figure D shows photographs of the body shape of each group of female mice; Figure E shows photographs of the tibia (upper) and femur (lower) for each group of female mice; and Figure F shows a bar chart of the tibia and femur length for each group of female mice. *P<0.05 compared to HFD, ns indicates no statistically significant difference between groups, and error bars represent standard deviation (SD).

[0045] Figure 4The results showed that *Focusia dorsalis* YG0564 significantly alleviated obesity in male rats on a high-fat diet. Figure A shows the net weight gain of male rats in each group; Figure B shows the net body length gain of male rats in each group; Figure C shows photographs of the body shape of male rats in each group; and Figure D shows a bar chart of the tibia and femur lengths of male rats in each group. *P<0.05 compared to HFD, ns indicates no statistically significant difference between groups, and error bars represent standard deviation (SD). Detailed Implementation

[0046] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention. Unless otherwise expressly stated, throughout the specification and claims, the term "comprising" or its variations such as "including" or "comprising of," etc., will be understood to include the stated elements or components, and does not exclude other elements or other components.

[0047] Furthermore, to better illustrate the present invention, numerous specific details are provided in the following detailed embodiments. Those skilled in the art should understand that the present invention can be practiced without certain specific details. In some embodiments, materials, elements, methods, and means well known to those skilled in the art are not described in detail in order to highlight the spirit of the invention.

[0048] Unless otherwise specified, all reagents or raw materials used in the following examples are commercially available.

[0049] The following experimental designs are used in all the following embodiments:

[0050] Newly weaned 21-day-old suckling mice (purchased from Vital River) were acclimatized for 2 days and then randomly divided into the following six groups:

[0051] ① Normal diet female mice (i.e., ND female mice): fed normal diet (purchased from Synergy Biotech, product number: XTCon50J), and each mouse was given 100μL PBS orally by gavage daily;

[0052] ② High-fat diet female mice (i.e., HFD female mice): fed 60% high-fat diet (purchased from Synergy Biotech, catalog number XTHF60), and each mouse was given 100μL PBS orally by gavage daily.

[0053] ③ High-fat diet probiotic female mice (i.e., HFD+YG0564 female mice): fed 60% high-fat diet (same as above), and at the same time, each mouse was given 1*10^9 CFU of live YG0564 bacteria resuspended in 100μLPBS orally by gavage (i.e., intervention started on the first day of modeling).

[0054] ④ Normal diet male mice (i.e., ND male mice): Feed normal diet (as above), and at the same time, each mouse is given 100μL PBS orally by gavage daily.

[0055] ⑤ High-fat diet male mice (i.e., HFD male mice): fed 60% high-fat diet (as above), and each mouse was given 100μL PBS orally by gavage daily;

[0056] ⑥ High-fat diet probiotic male mice (i.e., HFD+YG0564 male mice): Feed 60% high-fat diet, and at the same time, each mouse is given 1*10^9 CFU of live YG0564 bacteria resuspended in 100μL PBS orally by gavage (i.e., intervention begins on the first day of modeling).

[0057] In week 5 of modeling, i.e., when the mice were 8 weeks old, the probiotic intervention was discontinued in female mice on a high-fat diet and probiotics (i.e., HFD+YG0564 female mice), while the intervention was maintained in male mice on a high-fat diet and probiotics (i.e., HFD+YG0564 male mice). All of the above modeling was maintained for a total of 9 weeks, i.e., until the mice reached adulthood (i.e., 12 weeks old).

[0058] Example 1: Effect of *Focusella dorsalis* YG0564 on precocious puberty induced by a high-fat diet

[0059] For the above experimental groups, starting from the first day of modeling, observations were conducted twice a day, morning and evening, to record the time of the first vaginal opening in female mice and the time of prepuce separation in male mice, in order to determine the age of sexual maturity in mice.

[0060] The results are as follows Figure 1 As shown. Figure 1 Figure A shows the time of first vaginal opening in female mice and the time of prepuce separation in male mice in the ND and HFD groups. Figure 1 Figure B shows the time of first vaginal opening in female mice and the time of prepuce separation in male mice in the HFD and HFD+YG0564 groups.

[0061] Figure 1Figures A and B show that a high-fat diet advanced the time to sexual maturity in male mice from 41.8 days to 40.6 days, but the difference was not significant compared to male mice on a normal diet. In contrast, a high-fat diet significantly affected the time to sexual maturity in female mice, advancing it from 37.4 days to 31.9 days compared to female mice on a normal diet (p = 0.02). However, after intervention with strain YG0564, the age of sexual maturity in female mice on a high-fat diet returned to 36.9 days, and in male mice it returned to 41.8 days, both comparable to the normal diet group. These results indicate that strain YG0564 can effectively prevent and treat high-fat diet-induced precocious puberty.

[0062] Based on the above results, the following conclusions can be drawn:

[0063] (1) A high-fat diet can cause precocious puberty in mice, especially female mice.

[0064] (2) F. dorsalis YG0564 can significantly delay the sexual maturation time of mice on a high-fat diet, reaching a level comparable to that of the normal diet group, indicating that F. dorsalis YG0564 has a significant preventive or therapeutic effect on precocious puberty induced by a high-fat diet.

[0065] Therefore, *Focusia dorsalis* YG0564 can effectively reverse the premature sexual maturation caused by a high-fat diet, thus providing a new non-invasive method for the prevention and treatment of precocious puberty, and has significant clinical application value.

[0066] Example 2: *Focusia dorsalis* YG0564 can reduce the upregulation of sex hormone levels and delay follicle development induced by a high-fat diet.

[0067] Six-week-old model mice were euthanized and dissected to obtain hypothalamic and ovarian tissues. Total RNA was extracted from the hypothalamus and ovarian tissues using a Total RNA Extraction Kit (TransGen, China) according to the manufacturer's instructions. The RNA was then reverse transcribed into cDNA using a reverse transcription kit (Takara, Japan). Using this cDNA as a template, primer pairs specifically amplifying the sex hormone genes Kiss-1, GnRH, GnRHR, FSHR, Bmal1, CYP19A1, and the internal reference gene β-actin were used (specific primer sequences are shown in Table 1). A rapid real-time PCR kit (Tiangen, Beijing) and a real-time PCR amplification instrument were employed. qPCR was performed at 480°C to obtain Ct values. The expression levels of target genes were normalized using β-actin as an internal reference gene. Specifically, the relative expression levels of all genes were normalized using 2... -ΔΔCt The method (where ΔCt = Ct[target gene] - Ct[β-actin]) is used to calculate the value.

[0068] Table 1. Primer sequence information used for qPCR detection

[0069]

[0070]

[0071] The relative expression levels of various genes in hypothalamic and ovarian tissues are as follows: Figure 2 As shown in Figures A and B, it displays:

[0072] In female mice on a high-fat diet, the levels of the kissin receptor gene Kiss1R, gonadotropin-releasing hormone GnRH, and estrogen synthesis and secretion regulation gene Bmal1 in the hypothalamus, as well as the gonadotropin-releasing hormone receptor GnRHR, follicle-stimulating hormone receptor FSHR, and estrogen synthesis gene CYP19A1 in the ovary, were all higher than in the normal diet group. However, in high-fat diet mice treated with strain YG0564, the levels of these genes were significantly reduced, and could be reduced to the normal range.

[0073] In addition, the collected ovarian tissue was fixed with 4% paraformaldehyde (Solepro) and sent to a third-party pathology testing institution (Seville) for embedding, sectioning, and HE staining. Images were collected, and the number of mature follicles in each group of mice was counted based on the images. The results are as follows: Figure 2 As shown in Figure C, the number of mature follicles in the high-fat diet group was significantly increased, while the number of mature follicles in high-fat diet mice treated with strain YG0564 was significantly reduced.

[0074] Based on the above results, the following conclusions can be drawn:

[0075] (1) A high-fat diet can accelerate follicle development by upregulating the sexual maturation pathway, which in turn leads to precocious puberty.

[0076] (2) Fauciella dorsalis YG0564 can effectively delay the sexual maturation cycle and delay follicle development in mice on a high-fat diet. This result further confirms its preventive, alleviating and therapeutic effects on precocious puberty.

[0077] (3) The regulatory effect of F. dorsalis YG0564 on sexual maturation pathway and follicle development may be one of the key mechanisms for its prevention, relief and treatment of precocious puberty.

[0078] Example 3: *Focusia dorsalis* YG0564 can alleviate growth damage induced by a high-fat diet and promote growth and development in female mice.

[0079] Before initiating the animal model, the initial weight and body length (i.e., nose-tail length) of the female mice were recorded. During the modeling process, the weight and body length (i.e., nose-tail length) of the mice were recorded weekly. In the 5th week of modeling (i.e., when the mice were 8 weeks old), the probiotic intervention was discontinued in the high-fat diet probiotic female mice (i.e., HFD+YG0564 female mice). When the mice reached adulthood at 12 weeks of age, they were euthanized and dissected to remove and measure the bilateral femurs and tibias.

[0080] The results are as follows Figure 3 As shown. Figure 3 In the figure, A shows the net increase in body length of female mice in each group, B shows the net increase in body weight of female mice in each group, C shows the ovarian growth rate curve (cm / day) of female mice in each group, D shows the body shape photos of female mice in each group, E shows the measurement photos of the tibia (upper) and femur (lower) of female mice in each group, and F shows the statistical bar chart of the tibia and femur length of female mice in each group.

[0081] Depend on Figure 3 As can be seen, compared with a normal diet, a high-fat diet leads to reduced net height growth in female mice (see Figures A and D), shortened tibias (see Figure F), and premature and slowed growth rate (see Figure C). However, early intervention with strain YG0564 significantly promotes body length growth (see Figures A and D) and bone growth (see Figures E and F), maintaining a normal growth and development cycle in mice (see Figure C). Furthermore, we found that unlike male mice, which are highly sensitive to high-fat diets, female mice show tolerance to obesity induced by a high-fat diet, with minimal weight gain (see Figure B).

[0082] Based on the above results, the following conclusions can be drawn:

[0083] A high-fat diet significantly inhibited the growth and development of female mice, while intervention with strain YG0564 effectively alleviated this inhibition and promoted normal growth and development. This indicates that strain YG0564 plays an important role in improving high-fat diet-induced growth and development impairment. Crucially, after stopping the intervention with strain YG0564 at 8 weeks of age, the growth and development of female mice remained at normal levels until adulthood. This fully demonstrates the long-term protective effect of strain YG0564 after early puberty intervention, thus avoiding the need for long-term medication.

[0084] Example 4: *Focusia dorsalis* YG0564 can alleviate obesity induced by a high-fat diet in male rats.

[0085] Before initiating the animal model, the initial weight and body length (i.e., nose-tail length) of male mice were recorded; during the modeling process, weight and body length (i.e., nose-tail length) were recorded weekly. When the mice reached adulthood at 12 weeks of age, they were euthanized and dissected to remove and measure the bilateral femurs and tibias.

[0086] The results are as follows Figure 4As shown. Figure 4 In the figure, Figure A shows the net weight gain of male rats in each group, Figure B shows the net body length gain of male rats in each group, Figure C shows the body shape of male rats in each group, and Figure D shows the bar chart of tibia and femur length of male rats in each group.

[0087] Depend on Figure 4 It can be seen that young male mice fed a high-fat diet after weaning experienced accelerated weight gain, and by adulthood, their weight was significantly higher than that of the normal diet group, and their body size was larger (see Figures A and C). However, their net increase in body length and leg bone length were significantly lower than those of the normal diet group (see Figures B and D, p<0.05). In contrast, male mice fed a high-fat diet and treated with strain YG0564 had a weight and body size that were close to those of the normal diet group by adulthood (see Figures AD). Although their body length and bone length did not fully recover to normal levels, they still showed a recovery trend.

[0088] The above results indicate that a high-fat diet can lead to obesity in male rats, manifested as increased weight and body size, accompanied by restricted growth in body length and bone length; while intervention with strain YG0564 can significantly alleviate the obesity symptoms in male rats, reduce weight, and maintain body size.

[0089] Although strain YG0564 had limited effects on promoting body length and bone length in male rats on a high-fat diet, it was significant in improving obesity in male rats. Moreover, the effect of strain YG0564 in improving obesity remained stable throughout the experimental period, demonstrating its long-term effectiveness in treating obesity. This has important clinical significance and provides a potential probiotic therapy for treating obesity induced by a high-fat diet.

[0090] Furthermore, the above results also indicate that the therapeutic effect of strain YG0564 on obesity is related to gender, suggesting that gender-specific factors should be considered when applying it to different genders.

[0091] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. The use of Phocaeicola dorei YG0564 in the preparation of compositions for the prevention, relief and / or treatment of individual precocious puberty, characterized in that, Phocaeicola dorei YG0564 is deposited at the China General Microbiological Culture Collection Center (CGMCC), with the classification name Phocaeicola dorei, deposit date of June 7, 2023, and accession number CGMCC No. 27578.

2. The use according to claim 1, characterized in that, The individual is a mammal, preferably a female mammal, and more preferably a human; And / or, the individual precocious puberty is precocious puberty induced by a high-fat diet.

3. The use according to claim 2, characterized in that, The prevention, mitigation, and / or treatment of individual precocious puberty include reversing the timing of sexual maturation and delaying the timing of sexual maturation.

4. The use according to claim 3, characterized in that, Phocaeicola dorei YG0564 delays follicle development and thus sexual maturation by reducing sex hormone levels upregulated by a high-fat diet.

5. The use of Phocaeicola dorei YG0564 in the preparation of compositions for the prevention, mitigation, and / or treatment of impaired individual growth and development, characterized in that, Phocaeicola dorei YG0564 is deposited at the China General Microbiological Culture Collection Center (CGMCC), with the classification name Phocaeicola dorei, the deposit date being June 7, 2023, and the accession number being CGMCC No. 27578.

6. The use according to claim 4, characterized in that, The individual is a mammal, preferably a female mammal, and more preferably a human; And / or, the growth and development impairment is growth and development impairment caused by a high-fat diet.

7. The use of Phocaeicola dorei YG0564 in the preparation of compositions for the prevention and / or treatment of individual obesity or obesity-related diseases, characterized in that, Phocaeicola dorei YG0564 is deposited at the China General Microbiological Culture Collection Center (CGMCC), with the classification name Phocaeicola dorei, the deposit date being June 7, 2023, and the accession number being CGMCC No. 27578.

8. The use according to claim 7, characterized in that, The individual is a mammal, preferably a male mammal, and more preferably a human; And / or, the obesity is obesity caused by a high-fat diet; And / or, the obesity-related diseases are the following diseases caused by obesity: hyperlipidemia, hypertension, diabetes, coronary heart disease, non-alcoholic fatty liver disease, chronic obstructive pulmonary disease, polycystic ovary syndrome and / or hypothyroidism.

9. The use according to any one of claims 1-8, characterized in that, Phocaecoladorei YG0564 is the strain in the following forms: live bacteria, inactivated cells, lysate, and / or fermentation supernatant.

10. The use according to any one of claims 1-9, characterized in that, The composition is a pharmaceutical composition, or a food composition and / or health product composition for non-therapeutic purposes.

Images